olfactory receptor family 51 subfamily H member 2 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR51H2P profile across patient tissues and cancer cell-line models. OR51H2P expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, OR51H2P is differentially expressed in 3, with the highest sampling consensus in KICH. Additionally, OR51H2P RNA expression shows 6,277 significant gene co-expression associations, with the highest sampling consensus in KIRC. Together, these results highlight SKCM, KICH, and KIRC as cancer lineages where OR51H2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR51H2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR51H2P survival associations across molecular data types. OR51H2P RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR51H2P RNA expression–survival associations across cancer types. High OR51H2P expression shows unfavorable associations in SKCM, LUSC, PCPG and READ, but favorable associations in LAML and PRAD. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for OR51H2P RNA expression.
This table summarizes OR51H2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for OR51H2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR51H2P shows lower tumor expression in KIRC and higher tumor expression in KICH and PRAD. The KICH box plot shows higher OR51H2P RNA expression in tumor versus normal tissue (log2 FC = +0.234, t-test p = .019).
This table shows molecular features associated with OR51H2P in patient tissues and cancer cell lines. In patient samples, OR51H2P shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
